277 related articles for article (PubMed ID: 34471493)
1. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma.
Liu Q; Nie R; Li M; Li L; Zhou H; Lu H; Wang X
Comput Struct Biotechnol J; 2021; 19():4472-4485. PubMed ID: 34471493
[TBL] [Abstract][Full Text] [Related]
2. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract][Full Text] [Related]
3. Classification of lung adenocarcinoma based on stemness scores in bulk and single cell transcriptomes.
Liu Q; Lei J; Zhang X; Wang X
Comput Struct Biotechnol J; 2022; 20():1691-1701. PubMed ID: 35495113
[TBL] [Abstract][Full Text] [Related]
4. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer.
Lin BB; Lei HQ; Xiong HY; Fu X; Shi F; Yang XW; Yang YF; Liao GL; Feng YP; Jiang DG; Pang J
Comput Struct Biotechnol J; 2021; 19():4941-4953. PubMed ID: 34527198
[TBL] [Abstract][Full Text] [Related]
6. Gene set enrichment analysis identifies immune subtypes of kidney renal clear cell carcinoma with significantly different molecular and clinical properties.
Chen Z; Cao W; Luo J; Abdelrahman Z; Lu Q; Wang H; Wang X
Front Immunol; 2023; 14():1191365. PubMed ID: 37426638
[TBL] [Abstract][Full Text] [Related]
7.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
8. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
9. The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression.
Zhang Z; Li L; Li M; Wang X
Comput Struct Biotechnol J; 2020; 18():2438-2444. PubMed ID: 32905022
[TBL] [Abstract][Full Text] [Related]
10. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
13. Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma.
Shen K; Wang Q; Wang L; Yang Y; Ren M; Li Y; Gao Z; Zheng S; Ding Y; Ji J; Wei C; Zhang T; Zhu Y; Feng J; Qin F; Yang Y; Wei C; Gu J
Eur J Med Res; 2023 Sep; 28(1):352. PubMed ID: 37716991
[TBL] [Abstract][Full Text] [Related]
14. Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis.
He Y; Wang X
Comput Biol Med; 2023 Dec; 167():107591. PubMed ID: 37875043
[TBL] [Abstract][Full Text] [Related]
15. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
Zhang H; Song J; Dong J; Liu Z; Lin L; Wang B; Ma Q; Ma L
Front Genet; 2021; 12():551605. PubMed ID: 33732281
[No Abstract] [Full Text] [Related]
16. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
[TBL] [Abstract][Full Text] [Related]
18. Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
[TBL] [Abstract][Full Text] [Related]
19. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
20. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell transcriptomes.
Chen C; Luo J; Wang X
Med Oncol; 2022 Jun; 39(9):123. PubMed ID: 35716212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]